Kiniksa Pharmaceuticals Raises 2026 Revenue Guidance Following Strong ARCALYST Growth
Kiniksa Pharmaceuticals (KNSA) reported robust third-quarter 2026 financial results, characterized by a significant increase in net income to $47.3 million from $18.4 million the previous year. The company's primary product, ARCALYST, generated $286 million in net product revenue, marking a 58% year-over-year growth driven by increased physician adoption and patient penetration rates. Reflecting strong commercial execution, Kiniksa raised its full-year 2026 revenue guidance to a range of $1.045 billion to $1.050 billion. The company maintains a healthy liquidity position with $568.8 million in cash and short-term investments. Looking ahead, management is focusing on the clinical development of KPL-387 and KPL-1161, with pivotal Phase III data for KPL-387 expected in the second half of 2027.
Tickers: $KNSA
Topics: clinical development guidance net income product adoption revenue growth
Read the full article at Motley Fool
Part of the story Equinix Reports Strong Q3 2026 Results and Raises Full-Year Guidance (49 articles)